Stiefel Laboratories, the world’s largest independent dermatology company, was acquired by GlaxoSmithKline (GSK) in 2009. GSK had an existing presence in dermatology with products like Zovirax® and Bactroban®, and with the addition of Stiefel, a GSK company we are stronger, more competitive, and continue to be a driving force in dermatology around the world.
Stiefel, a GSK company, is committed to advancing dermatology and skin science around the world in order to help people better achieve healthier skin. Stiefel’s dedication to innovation, along with its focus on pharmaceutical, over-the-counter and aesthetic dermatology products, has established Stiefel as a world leader in the skin health industry.
Dermatological therapies from Stiefel, the leading company in Canada include
PrCLINDOXYL® Gel, PrNERISONE®, PrSTIEPROX® Shampoo and UREMOL®.
In an effort to respond to physicians’ growing aesthetic needs, Stiefel, a GSK company is pleased to offer REVALÉSKIN®, the next generation of super-antioxidant skin care for your patients’ rejuvenation needs. REVALÉSKIN® is the exclusive professional anti-aging line of skin care products exclusively formulated with the powerful, natural antioxidant ingredient CoffeeBerry™.
As Stiefel, a GSK company, we are proud to deliver an even stronger portfolio of prescription, consumer, and aesthetic skin health products to patients around the world.